Pacific Biosciences of California, Inc. (PACB)

PACB Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-309.85	-306.74	-314.25	-181.22
Depreciation & Amortization	53.35	26.53	17.32	11.59
Asset Writedown & Restructuring Costs	184.5	-	-	-
Loss (Gain) From Sale of Investments	-13.04	-12.84	-0.24	4.01
Stock-Based Compensation	71.04	72.12	78.61	73.36
Other Operating Activities	-151.47	20.71	9.32	-39.24
Change in Accounts Receivable	9.09	-17.83	5.46	-7.17
Change in Inventory	-8.32	-13.84	-33.91	-13.11
Change in Accounts Payable	1.41	0.21	1.03	6.36
Change in Unearned Revenue	-2.11	-10.42	-3.73	25.74
Change in Other Net Operating Assets	-40.65	-17.07	-22.81	8.5
Operating Cash Flow	-206.06	-259.17	-263.21	-111.18
Capital Expenditures	-6.19	-8.84	-16.75	-5.93
Cash Acquisitions	-	-0.1	-	-319.79
Sale (Purchase) of Intangibles	-	-	-0.18	-
Investment in Securities	130.19	13.55	133.01	-352.81
Investing Cash Flow	124	4.6	116.08	-678.53
Long-Term Debt Issued	-	-	-	895.54
Long-Term Debt Repaid	-50.69	-1.84	-1.61	-0.36
Net Debt Issued (Repaid)	-50.69	-1.84	-1.61	895.18
Issuance of Common Stock	7.7	204.52	11.23	326.65
Other Financing Activities	-	-93.79	-	-52.25
Financing Cash Flow	-42.99	108.89	9.62	1,170
Net Cash Flow	-125.04	-145.68	-137.51	379.87
Free Cash Flow	-212.25	-268.02	-279.96	-117.11
Free Cash Flow Margin	-137.81%	-133.66%	-218.20%	-89.73%
Free Cash Flow Per Share	-0.77	-1.06	-1.25	-0.57
Cash Interest Paid	14.81	15.69	14.05	6.93
Levered Free Cash Flow	-95.64	-311.67	46.5	-24.54
Unlevered Free Cash Flow	-87.26	-302.7	55.68	-16.71
Change in Working Capital	-40.58	-58.96	-53.97	20.33

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q